Catalent Signs Deal With AstraZeneca to Manufacture COVID-19 Vaccine Candidate

New Jersey-based Catalent has entered into an agreement with AstraZeneca (AZ) to manufacture the drug substance for AZ’s COVID-19 vaccine candidate, AZD1222, at its facility in Harmans, Md.  

The deal is an expansion of a previous agreement the companies signed in June, under which Catalent will provide large-scale vial filling and packaging of the vaccine from its facility in Anagni, Italy.

AZD1222 is currently in multiple trials around the world and is just entering a phase 3 U.S. study that aims to enroll 30,000 participants.